Genmab - ADR logo

GMAB

Genmab - ADR

$35.64

Earnings Summary

Revenue
$2119Mn
Net Profits
$465Mn
Net Profit Margins
21.94%
PE Ratio
43.2

Highlights

Revenue:

Genmab - ADR’s revenue jumped 34.03% since last year same period to $2119Mn in the Q1 2022. On a quarterly growth basis, Genmab - ADR has generated -19.09% fall in its revenue since last 3-months.

Net Profits:

Genmab - ADR’s net profit fell -57.57% since last year same period to $465Mn in the Q1 2022. On a quarterly growth basis, Genmab - ADR has generated -35.06% fall in its net profits since last 3-months.

Net Profit Margins:

Genmab - ADR’s net profit margin fell -68.34% since last year same period to 21.94% in the Q1 2022. On a quarterly growth basis, Genmab - ADR has generated -19.73% fall in its net profit margins since last 3-months.

PE Ratio:

Genmab - ADR’s price-to-earnings ratio after this Q1 2022 earnings stands at 43.2.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Genmab - ADR post its latest quarter earnings

EPS Estimate Current Quarter
0.91
EPS Estimate Current Year
0.91

Highlights

EPS Estimate Current Quarter:

Genmab - ADR’s earning per share (EPS) estimates for the current quarter stand at 0.91 - a -82.83% fall from last quarter’s estimates.

EPS Estimate Current Year:

Genmab - ADR’s earning per share (EPS) estimates for the current year stand at 0.91.

Key Ratios

Key ratios of the Genmab - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
0.11
Return on Assets (ROA)
0.09
Return on Equity (ROE)
0.18
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Genmab - ADR’s earning per share (EPS) fell -59.26% since last year same period to 0.11 in the Q1 2022. This indicates that the Genmab - ADR has generated -59.26% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Genmab - ADR’s return on assets (ROA) stands at 0.09.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Genmab - ADR’s return on equity (ROE) stands at 0.18.

Dividend Per Share (DPS):

Genmab - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
0.91
0.11
-87.91%

Company Information

Organisation
Genmab - ADR
Headquarters
Kalvebod Brygge 43, Koebenhavn V, Denmark
Employees
781
Industry
Health Technology
CEO
Jan van de Winkel